Skip to main content
. Author manuscript; available in PMC: 2013 Nov 5.
Published in final edited form as: Mol Cell Endocrinol. 2012 Aug 2;363(1-2):92–99. doi: 10.1016/j.mce.2012.07.012

Fig. 5.

Fig. 5

AR-containing complexes bind to the −1796/−1791 sequence of GnRH-E1. (A), Nuclear extracts from GT1-7 cells that had been transfected with AR and treated with R1881 were incubated with a radiolabeled probe containing the −1802/−1779 region of GnRH-E1, with or without antibody. Lane 1: free probe (FP); Lane 2: probe with nuclear extract; Lane 3, rabbit IgG; Lane 4, anti-AR antibody. Bands 4–6 represent AR-containing complexes; ss: super-shifted AR. (B), Sequences of the wild type (wt) and mutant oligonucleotide competitors. Box: putative HRE; overline: TPA-responsive site; bold/underline: mutations. (C), Nuclear extracts from GT1-7 cells that had been transfected with AR were incubated with a radiolabeled probe containing the −1802/−1779 region of GnRH-E1, with or without indicated unlabeled competitor. Lane 1: free probe (FP); Lane 2: probe with nuclear extract; Lane 3: unlabeled androgen response element (ARE) competitor; Lane 4: wild type (wt) unlabeled competitor; Lanes 5–10: indicated mutant unlabeled competitor. Bands 4–6 represent AR-containing complexes; NS: non-specific band.